61 related articles for article (PubMed ID: 26826383)
1. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling.
Yan H; Guo BY; Zhang S
Biochem Biophys Res Commun; 2016 Feb; 470(4):947-54. PubMed ID: 26826383
[TBL] [Abstract][Full Text] [Related]
2. STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs).
Liu J; Liu C; Ma Y; Pan X; Chu R; Yao S; Chen J; Liu C; Chen Z; Sheng C; Zhang K; Xue Y; Schiöth HB; Kong B; Zhang Q; Song K
Cancer Lett; 2024 Apr; 588():216700. PubMed ID: 38373690
[TBL] [Abstract][Full Text] [Related]
3. Targeting the tumour microenvironment in ovarian cancer.
Hansen JM; Coleman RL; Sood AK
Eur J Cancer; 2016 Mar; 56():131-143. PubMed ID: 26849037
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go.
Buchsbaum RJ; Oh SY
Cancers (Basel); 2016 Jan; 8(2):. PubMed ID: 26828520
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
Zhou B; Sun C; Li N; Shan W; Lu H; Guo L; Guo E; Xia M; Weng D; Meng L; Hu J; Ma D; Chen G
Int J Oncol; 2016 May; 48(5):2087-97. PubMed ID: 26983899
[TBL] [Abstract][Full Text] [Related]
6. A framework for advancing our understanding of cancer-associated fibroblasts.
Sahai E; Astsaturov I; Cukierman E; DeNardo DG; Egeblad M; Evans RM; Fearon D; Greten FR; Hingorani SR; Hunter T; Hynes RO; Jain RK; Janowitz T; Jorgensen C; Kimmelman AC; Kolonin MG; Maki RG; Powers RS; Puré E; Ramirez DC; Scherz-Shouval R; Sherman MH; Stewart S; Tlsty TD; Tuveson DA; Watt FM; Weaver V; Weeraratna AT; Werb Z
Nat Rev Cancer; 2020 Mar; 20(3):174-186. PubMed ID: 31980749
[TBL] [Abstract][Full Text] [Related]
7. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
8. Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022.
Liu J; Ma J; Zhang J; Li C; Yu B; Choe HC; Ding K; Zhang L; Zhang L
Front Oncol; 2023; 13():1173863. PubMed ID: 37324006
[TBL] [Abstract][Full Text] [Related]
9. Chronic inflammation, cancer development and immunotherapy.
Wen Y; Zhu Y; Zhang C; Yang X; Gao Y; Li M; Yang H; Liu T; Tang H
Front Pharmacol; 2022; 13():1040163. PubMed ID: 36313280
[TBL] [Abstract][Full Text] [Related]
10. Cryptotanshinone inhibits ovarian tumor growth and metastasis by degrading c-Myc and attenuating the FAK signaling pathway.
Guo H; Zhang W; Wang J; Zhao G; Wang Y; Zhu BM; Dong P; Watari H; Wang B; Li W; Tigyi G; Yue J
Front Cell Dev Biol; 2022; 10():959518. PubMed ID: 36247016
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness and acceleratory effect of macrophage inhibitory cytokine-1 on biliary tract cancer: an experimental biomarker analysis.
Sugimoto M; Suzuki R; Nozawa Y; Takagi T; Konno N; Asama H; Sato Y; Irie H; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Suzuki O; Hashimoto Y; Hikichi T; Ohira H
Cancer Cell Int; 2022 Aug; 22(1):250. PubMed ID: 35948981
[TBL] [Abstract][Full Text] [Related]
12. Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases.
Han L; Guo X; Du R; Guo K; Qi P; Bian H
J Ovarian Res; 2022 Jun; 15(1):75. PubMed ID: 35739532
[TBL] [Abstract][Full Text] [Related]
13. Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets.
Czekay RP; Cheon DJ; Samarakoon R; Kutz SM; Higgins PJ
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267539
[TBL] [Abstract][Full Text] [Related]
14. Immunological configuration of ovarian carcinoma: features and impact on disease outcome.
Fucikova J; Coosemans A; Orsulic S; Cibula D; Vergote I; Galluzzi L; Spisek R
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34645669
[TBL] [Abstract][Full Text] [Related]
15. NANOG Promotes Cell Proliferation, Invasion, and Stemness via IL-6/STAT3 Signaling in Esophageal Squamous Carcinoma.
Deng L; Zhang X; Xiang X; Xiong R; Xiao D; Chen Z; Liu K; Feng G
Technol Cancer Res Treat; 2021; 20():15330338211038492. PubMed ID: 34520294
[No Abstract] [Full Text] [Related]
16. The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.
Eckert MA; Orozco C; Xiao J; Javellana M; Lengyel E
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34201616
[TBL] [Abstract][Full Text] [Related]
17. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.
Wu F; Yang J; Liu J; Wang Y; Mu J; Zeng Q; Deng S; Zhou H
Signal Transduct Target Ther; 2021 Jun; 6(1):218. PubMed ID: 34108441
[TBL] [Abstract][Full Text] [Related]
18. The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment.
Ni Y; Zhou X; Yang J; Shi H; Li H; Zhao X; Ma X
Front Cell Dev Biol; 2021; 9():637675. PubMed ID: 34095111
[TBL] [Abstract][Full Text] [Related]
19. IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment.
Maia A; Gu Z; Koch A; Berdiel-Acer M; Will R; Schlesner M; Wiemann S
Mol Oncol; 2021 May; 15(5):1308-1329. PubMed ID: 33476079
[TBL] [Abstract][Full Text] [Related]
20. CD44 in Ovarian Cancer Progression and Therapy Resistance-A Critical Role for STAT3.
Martincuks A; Li PC; Zhao Q; Zhang C; Li YJ; Yu H; Rodriguez-Rodriguez L
Front Oncol; 2020; 10():589601. PubMed ID: 33335857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
